Northwest Biotherapeutics: Targeting Glioblastoma with Immunotherapy Print E-mail
By Brian Wilson - Lead Contributor   
Thursday, 13 June 2013 10:08
This morning, Northwest Biotherapeutics (NASDAQ: NWBO) announced the initiation of a 60-patient Phase I/II trial at the MD Anderson Cancer Center for the
newest version of their personalized cancer immunotherapy DCVax-Direct – here is the

Error. Page cannot be displayed. Please contact your service provider for more details. (18)

press release (link).
Read more...
 
Wednesday's Biotech Catalyst Trade Watch List Print E-mail
By Scott Matusow   
Wednesday, 12 June 2013 07:43
Today, I list 4 biotech companies with significant near-term catalysts ahead.
Read more...
 
Clovis / CO-1686 – Value, Derived From Data, Supports The Valuation Print E-mail
By Brian Wilson - Lead Contributor   
Tuesday, 11 June 2013 10:06
The recent doubling of shares of Clovis Oncology (NASDAQ: CLVS) after the company’s presentation at ASCO 2013 still leaves many biotech investors baffled at the market’s new, intrinsic ~$1.9 B valuation of the company’s early-stage oncology pipeline compounds CO-1686 and Rucaparib, although continuing analysis of the data seems to be supporting the new CLVS market cap quite nicely.
Read more...
 
OPKO: More Hidden Value in Partnerships & Equity Investments Print E-mail
By Brian Wilson - Lead Contributor   
Monday, 10 June 2013 11:11
Recent coverage provided for OPKO included a simple financial model that supported a surprisingly high (~$1 B) valuation for a Phase III pipeline product hGH-CTP (a modified version of human growth hormone) that was added to the company’s pipeline after the acquisition of PROLOR Biotechnologies.
Read more...
 
OPKO Looks Lucrative as Acquired hGH-CTP Moves Into Phase III Trials Print E-mail
By Brian Wilson - Lead Contributor   
Thursday, 06 June 2013 10:22
OPKO Health (NASDAQ: OPK) has been seeing a steady rise in short interest throughout the last few months – with the last measurement by NASDAQ coming in at 30.16 M shares on May 15th 2013 as speculators begin to question the premium that the market is placing on the company due to the involvement of 37.5% individual shareholder and famous biotech investor Dr. Phillip Frost.
Read more...
 
Cowen Questions Sales Growth of Biogen Idec’s MS Drug Tecfidera Print E-mail
By Brian Wilson-Lead Contributor   
Wednesday, 05 June 2013 07:55
Yesterday, Biogen Idec (NASDAQ: BIIB) was the worst performer amongst the larger pharmaceutical companies after Cowen analyst Eric Schmidt pointed that that the IMS prescription sales data for new prescriptions (NRx) of the company’s recently launched multiple sclerosis / MS drug Tecfidera (dimethyl fumarate) may be flawed due to double counting of patients were prescribed a new dose of the drug.
Read more...
 
Biotech Buyout Speculation Trius Could Be Acquired Very Soon Print E-mail
By Scott Matusow   
Monday, 03 June 2013 12:19
Trius Therapeutics, Inc. (TSRX) focuses on the discovery, development, and commercialization of antibiotics for serious infections. It develops tedizolid phosphate that has completed phase 3 clinical trial for the treatment of acute bacterial skin and skin structure infections; and completed phase 1 clinical trial for the treatment of pneumonia.
Read more...
 
Affymax Drops on NASDAQ Delisting & Criticism Print E-mail
By Brian Wilson - Lead Contributor   
Monday, 03 June 2013 10:31
In February 2013, Affymax (NASDAQ: AFFY) made headlines after a nationwide voluntary recall of the erythropoietic agent OMONTYS (peginesatide) after reports of extreme hypersensitivity reactions to the drug, as well as five deaths that were supposedly linked to the drug.
Read more...
 
Biotech Buyout Speculation Trius Could Be Acquired Very Soon Print E-mail
By Scott Matusow   
Monday, 03 June 2013 07:32
Trius Therapeutics, Inc. (TSRX) focuses on the discovery, development, and commercialization of antibiotics for serious infections.
Read more...
 
4 Top Small Cap Biotech Acquisition Targets Print E-mail
By Scott Matusow   
Friday, 31 May 2013 07:43
Today, I list small cap companies I believe are top acquisition targets for large pharma. I combine speculation, rumors and buzz I am hearing, and company financial position as a few factors for consideration.
Read more...
 
<< Start < Prev 21 22 23 24 25 26 27 28 29 30 Next > End >>

Page 29 of 55
BMR:1